Nintendo, Juno Therapeutics Among 5 Stocks Making Headlines Thursday

Juno Therapeutics Inc (NASDAQ:JUNO) shares are in the green after the journal Science Translational Medicine published an article reflecting promising JCAR014 clinical data. JCAR014 is a chimeric antigen receptor (CAR) T-cell treatment and one of Juno’s drug candidates for the potential treatment of patients with relapsed or refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia. 50% of the 18 patients whose results could be evaluated for the dose-finding study experienced a complete response from the use of JCAR014 in combination with the chemotherapy agents fludarabine and cyclophosphamide. Early results from the use of an intermediate dose of JCAR014 in combination with the above-mentioned agents has delivered even better results, with 64% of the 11 patients experiencing a complete response. The number of hedge funds in our system with holdings in Juno Therapeutics Inc (NASDAQ:JUNO) fell by three quarter-over-quarter to 11 at the end of June.

Gevo, Inc. (NASDAQ:GEVO) is deep in the red today after announcing its intention to execute a public offering of common stock and warrants, the size and pricing of which has not been disclosed. Gevo plans to use the funds for general corporate purposes and to fund working capital. News of the offering followed yesterday’s news that Gevo had entered into a heads of agreement with Deutsche Lufthansa AG to supply its alcohol-to-jet fuel. The heads of agreement is non-binding and subject to completion of a binding off-take agreement. Three funds that we track owned shares of Gevo, Inc. (NASDAQ:GEVO) at the end of the second quarter, up by one from the end of the previous quarter. As with all volatile stocks, due-diligence is a must before considering any trades.

ABM Industries, Inc. (NYSE:ABM) earned $0.54 per share for its third quarter of fiscal year 2016, beating estimates by $0.14. Revenue for the period was $1.3 billion, up by 3.8% year-over-year, and missing the consensus target by $10 million. Organic revenue increased by 2.2%, led by strong growth in the company’s Janitorial segment. Adjusted EBITDA for the quarter was $61.1 million, up from $49.1 million a year earlier, while adjusted EBITDA margin came in at 4.7%, topping the 3.9% mark from a year ago. For the full 2016 fiscal year, ABM’s management expects adjusted income from continuing operations of between $1.70 and $1.75 per share. 15 funds that Insider Monkey tracks were long ABM Industries, Inc. (NYSE:ABM) at the end of June.

Disclosure: None